123I-labeled 2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (123I-FP-
CIT) was approved for clinical use in 2011 by the Food and Drug Administration. 123I-FP …

Abstract Background [123 I] N-ω-fluoropropyl-2β-carbomethoxy-3β-{4-iodophenyl}
nortropane ([123 I] FP-CIT) single photon emission computed tomography (SPECT) is a …

Loss of striatal dopamine (DA) transporters in Parkinson's disease (PD) has been accurately
assessed in vivo by single-photon emission tomography (SPET) studies using [123 I] β-CIT …

Purpose Dopamine transporter (DAT) imaging is used to support the diagnosis of
neurodegenerative parkinsonian disorders. Specific medications have been reported to …

Purpose In routine practice, dopamine transporter (DAT) imaging is frequently used as a
diagnostic tool to support the diagnosis of Parkinson's disease or dementia with Lewy …

Dopamine transporter (DAT) imaging with 123I-FP-CIT (123I-N-ω-fluoropropyl-2β-
carbomethoxy-3β-(4-iodophenyl) nortropane) SPECT is frequently used to detect loss of …

Parkinson's disease is characterized by degeneration of dopaminergic neurons, resulting in
loss of dopamine transporters in the striatum. Recently, the tracer 123l-/Vo)-fluoropropyl-2ß …

Although the diagnosis of Parkinson's disease (PD) is essentially clinical, the
implementation of imaging techniques can improve diagnostic accuracy. While some …

Current SPECT radioligands available for in vivo imaging of the dopamine transporter (DAT)
also show affinity for monoamine transporters other than DAT, especially the serotonin …

Parkinson's disease is characterized by degeneration of dopamine (DA) neurons and their
terminals. Since these neurons contain dopamine transporters (DAT), radioligands that bind …